(NYSE:VRX) according to the research report released by the firm to its investors. The daily volume was measured at 1,312,146 shares. (NYSE:VRX) most recently reported earnings of $2.34 per share for the period ending 2015-03-31 compared to $1.93 for the one year prior fiscal quarter.
Gold futures lost 1% today to settle near US$1,132 and five year lows. The stock was purchased at an average cost of $260.63 per share, for a total transaction of $260,630.00. A total of 10 Wall Street analysts projections have been taken into account in order to arrive at this number. Guggenheim now has a $300.00 price objective on the specialty pharmaceutical company’s stock. Analysts at Howard Weil initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Friday, July 10th.
After three years of political and economic instability, Egypt is trying to resume growth, which could reach 4% in 2014/2015 with a set target rate of 7% in 2018. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. Analysts at Scotiabank reiterated an outperform rating and set a $290.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Sunday, July 12th. Finally, analysts at JPMorgan Chase & Co. reiterated a buy rating and set a $250.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Friday, June 26th.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the Officer (Executive Vice President) of Valeant Pharmaceuticals global, Inc., Rosiello Robert L. had purchased shares worth of $2,999,379 in a transaction dated on June 12, 2015. Its main markets are in the United States, Canada, Mexico, Brazil, Europe and Australia. Within its U.S. Dermatology segment and Branded Generic – Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication.
Valeant, which built its portfolio through buying up smaller drugmakers, signed its biggest ever acquisition in March, when it offered $11 billion to buy Salix Pharmaceuticals. In July 2014, the Company acquired PreCision Dermatology, Inc.